Avacta Life Sciences Limited
  • About
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News Therapeutics
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

Therapeutics

17 Jan 2023

Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Investors | Therapeutics
19 Dec 2022

Avacta to Host Therapeutics Division Science Day on 23rd February 2023

Investors | Therapeutics
31 Oct 2022

Avacta to Present at Virtual Theranostics FAP Summit

Investors | Therapeutics
05 Sep 2022

AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration

Investors | Therapeutics
01 Sep 2022

Phase I clinical study of AVA6000 to advance to the fourth cohort

Investors | Therapeutics
21 Jul 2022

AffyXell Successfully Completes Funding Round

Investors | Therapeutics
30 Jun 2022

LG Chem renews license triggering payment to Avacta

Investors | Therapeutics
29 Jun 2022

Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin

Investors | Therapeutics
16 May 2022

AffyXell expands its strategic partnership with GenScript ProBio

Investors | Therapeutics
11 May 2022

Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus

Investors | Therapeutics

Posts navigation

Older posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us

Avacta Diagnostics

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Therapeutics

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3871 9700

Investor Enquiries

FTI Consulting
200 Aldersgate
Aldersgate Street
London
EC1A 4HD

Email

Twitter | Linkedin

©2023 Avacta Life Sciences Limited. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok